QIAGEN Strengthens QIAstat-Dx With New Barcelona Site

Drive Growth in Infectious Diseases and Precision Medicine Testing

02-Dec-2024 - QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business. Set to open in early 2026, the new site will cover the ...

Roche lays the foundation for the diagnostics production of the future in Germany

Investment of more than 600 million euros in a high-tech production center - Roche's largest single investment in Germany to date

29-Nov-2024 - Roche lays the foundation stone for one of Europe's most modern production centers for high-quality diagnostic input materials on the campus of its biotechnology center in Penzberg, Upper Bavaria. The company is investing more than 600 million euros - Roche's largest single investment in Germany. ...

New nanosensors make diagnostic procedures more sensitive

The nanosensors can be used to track reactions with invisible light, saving materials and time

16-Feb-2024 - The Fraunhofer Institute for Microelectronic Circuits and Systems IMS and Ruhr University Bochum, Germany, have developed a process that enables a new form of signal amplification for diagnostic tests. Through the advanced use of luminescent single walled carbon nanotubes in bioanalytics, test ...

Glow sticks – Not just for parties anymore

University of Houston researcher using popular party favor to detect biothreats for US Navy

12-Jan-2024 - Remember that party where you were swinging glow sticks above your head or wearing them as necklaces? Fun times, right? Science times, too. Turns out those fun party favors are now being used by a University of Houston researcher to identify emerging biothreats for the United States Navy. It’s ...

Start-up competition m4 Award announces winners

2.5 million euros for five research teams from Bavaria

26-Oct-2023 - The five winners of this year's m4 Award pre-founding competition have been announced. Each winning team will receive 500,000 euros for their project to solve urgent medical challenges. The award was announced by BioM together with the Bavarian State Ministry of Economic Affairs, Regional ...

How a CRISPR protein might yield new tests for many viruses

18-Jan-2023 - In a first for the genetic toolset known as CRISPR, a recently discovered protein has been found to act as a kind of multipurpose self-destruct system for bacteria, capable of degrading single-stranded RNA, single-stranded DNA and double-stranded DNA. With its abilities to target so many types of ...

Hope for first blood test to detect deadly heart inflammation

£50 blood test could improve diagnosis of myocarditis and help patients get lifesaving treatment earlier

29-Nov-2022 - The first blood test to diagnose inflammation of the heart muscle (myocarditis) could be in use in as little as a year, following the discovery of a molecular signal in the blood by Queen Mary University of London researchers funded by the British Heart Foundation (BHF). The research, published ...

New test may predict COVID-19 immunity

Paper test measures the level of neutralizing antibodies in a blood sample and could help people decide what protections they should take against infection

12-Aug-2022 - Most people in the United States have some degree of immune protection against Covid-19, either from vaccination, infection, or a combination of the two. But, just how much protection does any individual person have? MIT researchers have now developed an easy-to-use test that may be able to ...

Molzym Announces Double-Digit Million EUR Capital Increase

07-Jul-2022 - Molzym is proud to announce a double-digit million EUR investment by a large single family office. The capital will be deployed for the international business expansion, in particular for market entry and expansion in the US and China as well as further expanding its presence in Europe. ...

Covalab invests more than €1 million in bioproduction operations for antibodies for Covid-19 diagnostics

Company’s BioDiaThera project received almost €500,000 in subsidies as part of French ‘Capacity Building’ scheme

25-May-2022 - Covalab, a biotechnology company that specializes in the development and production of recombinant proteins and antibodies for diagnostics and therapeutics, announces that its BioDiaThera project has been awarded €491,152 ($520k) in funding as part of the French ‘Capacity Building’ scheme; part ...